Population variation in VKORC1 haplotype structure

被引：42

作者：

Marsh, S ^{[1
]}

King, CR ^{[1
]}

Porche-Sorbet, RM ^{[1
]}

Scott-Horton, TJ ^{[1
]}

Eby, CS ^{[1
]}

机构：

[1] Washington Univ, Sch Med, St Louis, MO 63110 USA

来源：

JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2006年 / 4卷 / 02期

关键词：

D O I：

10.1111/j.1538-7836.2006.01759.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：473 / 474

页数：2

共 7 条

[1] A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin [J].

D'Andrea, G ;

D'Ambrosio, RL ;

Di Perna, P ;

Chetta, M ;

Santacroce, R ;

Brancaccio, V ;

Grandone, E ;

Margaglione, M .

BLOOD, 2005, 105 (02) :645-649

[2] The influence of ethnicity on warfarin dosage requirement [J].

Dang, MTN ;

Hambleton, J ;

Kayser, SR .

ANNALS OF PHARMACOTHERAPY, 2005, 39 (06) :1008-1012

[3] Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin [J].

Gage, BF ;

Eby, C ;

Milligan, PE ;

Banet, GA ;

Duncan, JR ;

McLeod, HL .

THROMBOSIS AND HAEMOSTASIS, 2004, 91 (01) :87-94

[4] Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose [J].

Rieder, MJ ;

Reiner, AP ;

Gage, BF ;

Nickerson, DA ;

Eby, CS ;

McLeod, HL ;

Blough, DK ;

Thummel, KE ;

Veenstra, DL ;

Rettie, AE .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (22) :2285-2293

[5] The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:: proposal for a new dosing regimen [J].

Sconce, EA ;

Khan, TI ;

Wynne, HA ;

Avery, P ;

Monkhouse, L ;

King, BP ;

Wood, P ;

Kesteven, P ;

Daly, AK ;

Kamali, F .

BLOOD, 2005, 106 (07) :2329-2333

[6] Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and γ-glutamyl carboxylase) gene variants with warfarin sensitivity [J].

Shikata, E ;

Ieiri, I ;

Ishiguro, S ;

Aono, H ;

Inoue, K ;

Koide, T ;

Ohgi, S ;

Otsubo, K .

BLOOD, 2004, 103 (07) :2630-2635

[7] Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population [J].

Veenstra, DL ;

You, JHS ;

Rieder, MJ ;

Farin, FM ;

Wilkerson, HW ;

Blough, DK ;

Cheng, G ;

Rettie, AE .

PHARMACOGENETICS AND GENOMICS, 2005, 15 (10) :687-691

← 1 →